Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sichuan Biokin Pharmaceutical Co Ltd
Deferred Income Tax
Sichuan Biokin Pharmaceutical Co Ltd
Deferred Income Tax Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Deferred Income Tax | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Deferred Income Tax
¥4.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
119%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Deferred Income Tax
¥72.3m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Deferred Income Tax
¥53m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Deferred Income Tax
¥117m
|
CAGR 3-Years
14%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Deferred Income Tax
¥148.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Deferred Income Tax
¥152.1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
44%
|
|
Sichuan Biokin Pharmaceutical Co Ltd
Glance View
Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.
See Also
What is Sichuan Biokin Pharmaceutical Co Ltd's Deferred Income Tax?
Deferred Income Tax
4.3m
CNY
Based on the financial report for Dec 31, 2025, Sichuan Biokin Pharmaceutical Co Ltd's Deferred Income Tax amounts to 4.3m CNY.
What is Sichuan Biokin Pharmaceutical Co Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 5Y
119%
Over the last year, the Deferred Income Tax growth was 123%.